Tarlatamab - How much does one Imdelltra cost?

Tarlatamab-Imdelltra is a new immunotherapy drug indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed during or after platinum-based chemotherapy. Small cell lung cancer is a highly aggressive lung tumor. Traditional therapies often have difficulty controlling the course of the disease, with high recurrence rates and limited treatment options. The emergence of talatumumab provides a new immunotherapy idea for clinical practice.

The drug uses bispecific antibody technology to connectT cells with tumor cells expressing specific targets, thereby activating the patient's own immune system to accurately attack the tumor. This mechanism is different from traditional chemotherapy or targeted therapy, and is closer to the way of "awakening the body's self-anti-cancer ability", so it has attracted much attention in the international medical community.

At the application level, talatumumab is mainly suitable for patients with small cell lung cancer who are resistant to or relapsed with standard platinum-based chemotherapy. Due to the rapid progression of the disease and the limited treatment window, the ability to provide new treatment options is of great significance to prolong survival and improve quality of life. At the same time, international clinical experts generally believe that talatumumab is expected to be used in combination with other immunological drugs or chemotherapy drugs in the future to further improve the efficacy.

As for price, talatumumab is not currently available in the country, and naturally cannot be included in medical insurance. According to overseas public information, the specifications of the drug in the U.S. market are 1mg and 10mg. The price of 1mg is about 25,000 yuan, and the price of 10mg is about 148,000 yuan. Since there are no generic versions of this drug on the market yet, patients can basically only rely on the original version if they need to use it. Although the price is high, it is still within reasonable international drug pricing logic in terms of medical value and treatment needs for rare diseases.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html